Editor’s introduction to the initial issue of the 14th volume of GaBI Journal

Author(s): Robin Thorpe, PhD, FRCPath

In this first issue of 2025, we have some controversial criticism of an article previously published in GaBI Journal [1}, as well as a paper on pricing of biosimilars/biologicals after patent expiry and a meeting report on claimed weakening of FDA regulatory standards for biosimilars and its perceived effects on undermining physician confidence in biosimilar […]

Read more →